SCHEDULE 13G/A: Millennium Management Entities Disclose 5.8% Stake in Cumberland Pharmaceuticals

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly disclosed a beneficial ownership of 5.8% in Cumberland Pharmaceuticals Inc.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 809,897 shares of Common Stock, no par value, in Cumberland Pharmaceuticals Inc.
• This aggregate amount represents 5.8% of the class of securities.
• The reporting persons share both voting and dispositive power over all 809,897 shares.
• The securities were not acquired for the purpose of changing or influencing the control of Cumberland Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. The presence of a significant institutional investor can be seen as a positive signal, but the filing itself is purely informational.

Positives

• A significant beneficial ownership stake by a prominent investment firm like Millennium Management and its affiliates could be viewed as a vote of confidence in Cumberland Pharmaceuticals Inc.

Future Outlook

This document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by reporting persons)

Industry Context

This filing reflects a standard disclosure of a significant passive investment stake by a hedge fund in a publicly traded pharmaceutical company. It does not provide broader industry trends but indicates institutional interest in the sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major investment firm like Millennium Management may influence investor perception and potentially the stock price, signaling institutional interest.

Key Dates

Keywords

Cumberland Pharmaceuticals, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor